Company attributes
Venture Capital Firm attributes
Other attributes
Global Life Science Ventures is a venture capital firm focusing on the life science sector. The firm is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The firm was founded in 1996 and is based in Munich, Germany.
Global Life Science Ventures also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance, advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in Germany and Switzerland, GLSV acted as one team with a global perspective. The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation.
Global Life Sciences Ventures' investments include Binx Health, Santaris Pharma, Action Pharma, Coapt Systems, Agendia, Nitec Pharma, Pieris Pharmaceuticals, NeurogesX and Spinal Cord Therapeutics.
Their exited investments include Santaris Pharma, NeurogesX, Cytos, Zalicus, Coapt Systems, Coley Pharmaceutical Group, Roche Glycart, Intercell and Pieris Pharmaceuticals.
